You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Rusalatide Acetate (TP508) Mitigation Effect on Radiation Induced Keratopathy
SBC: AFFIRMED PHARMA, LLC Topic: NEIAbstract Radiation induced keratopathy results in significant ocular surface disease, stem cell deficiency, vision loss, discomfort, and subsequent poor quality of life, affecting up to 23% of patients receiving radiation therapy for head and neck malignancies [1]. Studies have pointed out functional roles of corneal neurons and secretory cells of the lacrimal gland in the etiology of radiation in ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Optimizing brain penetrance of caspase-6 inhibitors to treat neurodegenerative diseases
SBC: ELGIA THERAPEUTICS, INC. Topic: RPROJECT SUMMARY/ABSTRACT The cysteine protease caspase-6 (Casp6) has been associated with neurodegenerative diseases for over fifteen years. In Alzheimer’s disease (AD), Casp6 is colocalized with amyloid plaques and tau tangles in human brain, and both human and animal model data indicate that activated Casp6 contributes to neuronal inflammation, neurodegeneration, and cleavage of proteins to to ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Evaluating the efficacy of Butyric acid pro-drug nanoparticle in retinal neuroprotection
SBC: Nutriforward, LLC Topic: 100Project Summary Choroidal neovascularization (CNV) occurs in both age-related macular degeneration (AMD) and diabetic retinopathy (DR). While anti-VEGF treatment has improved the visual outcome considerably, they are far from achieving a 100% success rate (non-responsiveness between 8 and 50%). Inherited retinal degenerations (IRDs) are a group of heterogeneous, progressive, visually debilitating ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Glove-based Tactile Streaming of Braille Characters and Digital Images for the Visually Impaired
SBC: HAPTX INC Topic: NEIThis project will achieve a computerized system that supplies digital content, both lexical and graphical, suitable for children, students and working adults of the Visually Impaired (VId) community, to increase their autonomy and potentiate their Quality of Life and societal contribution. While there is notable academic research, such as a high-density pin display tablet, there is no commercial, ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A decellularized porcine placenta matrix hydrogel for management of radiation-induced proctitis
SBC: Briopryme Biologics, Inc. Topic: 102PROJECT SUMMARY Radiation therapy is a widely used treatment modality for pelvic malignancies such as prostate and cervical cancer; however, the high doses needed to confer therapeutic benefit often inflict significant damage on the normal issue in and surrounding the radiation field. The most frequent complication of pelvic radiation is proctitis, which nearly all patients experience acutely and ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Testing the effects of a selective calpain-2 inhibitor on spontaneous recurrent seizures in mouse models of epilepsy
SBC: NEURAEGIS INC Topic: 103AbstractEpilepsy is the most prevalent neurological diseases after migraines. Current antiepileptic drug treatments mainly attempt to reduce excitation or enhance inhibition in order to control seizures. Unfortunately, such therapeutics result in a number of undesirable side-effects, and demonstrate limited efficacy against drug- resistant cases of epilepsy. So far, no treatment has been developed ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of drug conjugates of R-spondin peptibodies for the treatment of colorectal cancer
SBC: WNTRIX INC Topic: 102PROJECT SUMMARY Colorectal cancer is still a major cause of cancer-related death in the world and only a small subset of patients benefits from therapy by immune checkpoint inhibitors. Antibody–drug conjugates (ADCs) are monoclonal antibodies (mAbs) that are covalently linked to cell-killing drugs and have emerged as a major modality in anti-cancer treatment. This approach combines high specific ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Clusterin Targeting of Ocular Surface Disease
SBC: PROTERIS BIOTECH, INC. Topic: NEIPROJECT SUMMARYThe ocular surface (OcS) comprises the stratified squamous epithelia of the cornea/conjunctiva, its adnexa, and the overlying tear film. OcS disease disrupts the normal developmental progression, maturation, and turnover of OcS epithelia, causing “epitheliopathy” characterized by cell damage, barrier disruption and programmed cell death. OcS disease initiated by tear dysfunction ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Audiom: Developing an Indoor Non-Visual Mapping System
SBC: XR NAVIGATION INC Topic: NEIProject Abstract Indoor navigation for blind and visually impaired individuals (BVIs) within unfamiliar locations is typically an incredibly anxiety-provoking and stressful experience for numerous reasons, e.g., inaccessible signage including directories and venue maps, and if braille signs do exist, they are difficult to find, lack directional information, and are useless to the BVIs who do not r ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Developing RNA therapeutics for rare neurodevelopmental disorders
SBC: Dayi Therapeutics, Inc. Topic: NICHDPROJECT SUMMARY Developing RNA therapeutics for rare neurodevelopmental disorders Monogenic diseases caused by mutations in single genes are individually rare, but collectively common affecting 10% of the world population. Many of these diseases are disabling or even life threatening with no available treatment. The underlying molecular mechanisms vary. Both loss of gene function and gain of toxic ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health